Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Recommendation of "Hold" by Analysts

Key Points

• Pacira BioSciences, Inc. received a **consensus recommendation** of "Hold" from seven brokerages, with one **sell**, two **hold**, and four **buy** ratings.
• The company's stock, traded under NASDAQ:PCRX, has a **12-month price range** between $16.00 and $27.64, and opened at **$23.02** recently.
• Pacira BioSciences reported an **EPS of $0.74** for the last quarter, slightly above the consensus estimate, with a revenue of **$181.10 million** despite a negative net margin of **18.08%**.

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) has been given a consensus recommendation of "Hold" by the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $33.40.

PCRX has been the subject of several recent research reports. Weiss Ratings reissued a "sell (d)" rating on shares of Pacira BioSciences in a research report on Wednesday, October 8th. Truist Financial upgraded shares of Pacira BioSciences from a "hold" rating to a "buy" rating and set a $30.00 price objective for the company in a research note on Friday, July 25th. Finally, Zacks Research upgraded shares of Pacira BioSciences from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 14th.

Pacira BioSciences Stock Performance

PCRX stock opened at $23.02 on Tuesday. The company has a quick ratio of 1.91, a current ratio of 2.38 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -8.28 and a beta of 0.40. Pacira BioSciences has a 12 month low of $16.00 and a 12 month high of $27.64. The firm has a 50 day moving average of $25.33 and a two-hundred day moving average of $24.78.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.73 by $0.01. The company had revenue of $181.10 million during the quarter, compared to the consensus estimate of $183.11 million. Pacira BioSciences had a negative net margin of 18.08% and a positive return on equity of 13.29%. The company's revenue for the quarter was up 1.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.96 earnings per share. Pacira BioSciences has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Pacira BioSciences will post 2.41 EPS for the current fiscal year.

Insider Buying and Selling at Pacira BioSciences

In other news, Director Marcelo Bigal sold 4,912 shares of the business's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $23.67, for a total value of $116,267.04. Following the completion of the sale, the director directly owned 11,393 shares in the company, valued at approximately $269,672.31. The trade was a 30.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 6.40% of the company's stock.

Institutional Trading of Pacira BioSciences

Institutional investors and hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Pacira BioSciences in the first quarter worth $51,000. US Bancorp DE raised its stake in Pacira BioSciences by 31.0% during the 1st quarter. US Bancorp DE now owns 2,270 shares of the company's stock valued at $56,000 after purchasing an additional 537 shares during the last quarter. Brooklyn Investment Group raised its stake in Pacira BioSciences by 372.2% during the 1st quarter. Brooklyn Investment Group now owns 2,238 shares of the company's stock valued at $56,000 after purchasing an additional 1,764 shares during the last quarter. Wealthquest Corp acquired a new position in Pacira BioSciences during the 1st quarter valued at $59,000. Finally, Strs Ohio acquired a new position in Pacira BioSciences during the 1st quarter valued at $75,000. 99.73% of the stock is currently owned by institutional investors and hedge funds.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.